Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027
The global overactive bladder treatment market is projected to reach USD 4.2 billion by 2027 from USD 3.5 billion in 2022, at a CAGR of 3.6% during the forecast period. Rising prevalence of overactive bladder across the globe coupled with rising awareness about treatment options available is driving the growth of the market. Additionally, use of neuromodulation techniques for the treatment of OAB is further expected to have significant positive impact.
“Mirabergon segment dominates the overactive bladder (OAB) treatment market in 2021.”
Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing to the lesser side-effects associated with this drug compared to other drug classes available in the market. Furthermore, neuromodulation segment is expected to grow at faster pace owing to launch of new SNM & PTNS for OAB in market.
“The idiopathic overactive bladder segment will witness the highest growth in overactive bladder treatment market during the forecast period.”
Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for the treatment.
“North America held dominant share in 2021.”
Geographically, the overactive bladder (OAB) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share in the OAB treatment market. North America holds majority of the key market players leading to maturity of OAB treatment market in this region. Furthermore, favorable reimbursement policies in US is one of the leading factor projecting market growth in North America.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the global overactive bladder treatment market. It aims at estimating the size and future growth potential of the market across different segments, such as type, disease type and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total cell analysis market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
“Mirabergon segment dominates the overactive bladder (OAB) treatment market in 2021.”
Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing to the lesser side-effects associated with this drug compared to other drug classes available in the market. Furthermore, neuromodulation segment is expected to grow at faster pace owing to launch of new SNM & PTNS for OAB in market.
“The idiopathic overactive bladder segment will witness the highest growth in overactive bladder treatment market during the forecast period.”
Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for the treatment.
“North America held dominant share in 2021.”
Geographically, the overactive bladder (OAB) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share in the OAB treatment market. North America holds majority of the key market players leading to maturity of OAB treatment market in this region. Furthermore, favorable reimbursement policies in US is one of the leading factor projecting market growth in North America.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type – Supply Side: 80.0%, Demand Side: 20.0%
- By Designation – Managers: 45.0%, CXOs & Directors:30.0%, Excecutives:25.0%
- By Region - North America: 55%, Europe: 20%, Asia Pacific: 10%, Latin America: 10%, and the Middle East and Africa: 5%
- Astellas Pharma Inc. (Japan)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Pfizer Inc. (US)
- Abbvie Inc. (US)
- Viatris Inc. (US)
- Hisamitsu Pharmaceutical Co., Inc. (Japan)
- Johnson & Johnson Services, Inc. (US)
- Endo Pharmaceuticals Inc. (Ireland)
- Lupin (India)
- Amneal Pharmaceuticals Llc (US)
- Sun Pharmaceutical Industries Ltd. (India)
- Glenmark (India)
- Macleods Pharmaceuticals Ltd (India)
- Medtronic (Ireland)
- Ajanta Pharma (India)
- Granules India Limited (India)
- Urovant Sciences (US)
- Apotex Inc. (Canada)
- Laborie (US)
- Intas Pharmaceuticals Ltd. (India)
- Bayer Ag (Germany)
- Medytox (South Korea)
- Altherx Pharmaceuticals (US)
- Taiho Pharmaceutical Co., Ltd. (Japan)
- Hugel, Inc. (South Korea)
This report provides a detailed picture of the global overactive bladder treatment market. It aims at estimating the size and future growth potential of the market across different segments, such as type, disease type and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total cell analysis market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on cell analysis offered by the top 25 players in the cell analysis market. The report analyses the overactive bladder treatment market by type, disease type and region.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various cell analysis across key geographic regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the overactive bladder (OAB) treatment market.
- Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the overactive bladder treatment market.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.1.1 PRIMARY RESEARCH
FIGURE 2 OVERACTIVE BLADDER TREATMENT MARKET: PRIMARY RESPONDENTS
2.1.2 TOP-DOWN AND BOTTOM-UP APPROACHES
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION
2.2 DATA TRIANGULATION APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.2.1 SECONDARY RESEARCH
2.2.2 COVID-19-SPECIFIC ASSUMPTIONS
2.3 RESEARCH LIMITATIONS
2.4 RISK ASSESSMENT
2.5 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
2.5.1 SUPPLY SIDE
2.5.2 DEMAND SIDE
2.5.2.1 Insights from primary experts
3 EXECUTIVE SUMMARY
FIGURE 6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE
2022 VS. 2027 (USD MILLION)
FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE OVERACTIVE
BLADDER TREATMENT MARKET
4 PREMIUM INSIGHTS
4.1 OVERACTIVE BLADDER TREATMENT MARKET OVERVIEW
FIGURE 9 RISING PREVALENCE OF OVERACTIVE BLADDER SYNDROME AND FAVORABLE REIMBURSEMENT POLICIES ARE KEY FACTORS DRIVING MARKET GROWTH
4.2 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY TYPE AND COUNTRY (2021)
FIGURE 10 MIRABEGRON ACCOUNTED FOR THE LARGEST SHARE OF
THE ASIA PACIFIC MARKET IN 2021
4.3 OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY DISEASE TYPE, 2022 VS. 2027
FIGURE 11 IDIOPATHIC OVERACTIVE BLADDER SYNDROME SEGMENT WILL
CONTINUE TO DOMINATE THE MARKET IN 2027
4.4 OVERACTIVE BLADDER TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 12 US TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 13 OVERACTIVE BLADDER TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 OVERACTIVE BLADDER TREATMENT MARKET: IMPACT ANALYSIS
5.2.1 MARKET DRIVERS
5.2.1.1 Rising prevalence of overactive bladder syndrome
5.2.1.2 Rapidly aging population and subsequent rise in incidence of diseases characterized by OAB
FIGURE 14 PROJECTED GROWTH IN THE ELDERLY POPULATION ABOVE 60, 2015 VS. 2030 VS. 2050
5.2.1.3 Development and use of innovative intravesical therapies
5.2.1.4 Growing R&D investments and the launch of novel therapies
in the coming years
5.2.2 MARKET RESTRAINTS
5.2.2.1 Frequent product recalls
5.2.2.2 Increased side effects of anticholinergic drugs
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Novel treatments, robust pipelines, and patent cliff of certain drugs
5.2.4 MARKET CHALLENGES
5.2.4.1 Social stigma and lack of awareness about OAB
5.3 IMPACT OF UNCERTAINTIES ON THE OVERACTIVE BLADDER TREATMENT MARKET
FIGURE 15 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE OVERACTIVE BLADDER TREATMENT MARKET
5.4 IMPACT OF COVID-19 ON THE OVERACTIVE BLADDER TREATMENT MARKET
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 16 REVENUE SHIFT AND NEW POCKETS FOR THE OVERACTIVE BLADDER TREATMENT MARKET
5.6 VALUE CHAIN ANALYSIS
FIGURE 17 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 18 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF
PROMINENT COMPANIES
5.8 ECOSYSTEM ANALYSIS
FIGURE 19 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY
FIGURE 20 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES INDUSTRY
5.9 REGULATORY SCENARIO
5.9.1 PHARMACEUTICAL INDUSTRY
5.9.1.1 Regulatory requirements
5.9.1.1.1 EU regulations
5.9.1.1.2 US regulations
5.9.2 MEDICAL DEVICE INDUSTRY
5.9.2.1 Regulatory requirements
5.9.2.1.1 EU regulations
5.9.2.1.2 US regulations
TABLE 2 LIST OF REGULATORY AUTHORITIES
5.10 TECHNOLOGY ANALYSIS
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 3 OVERACTIVE BLADDER TREATMENT MARKET: LIST OF
CONFERENCES AND EVENTS
5.12 PATENT ANALYSIS
FIGURE 21 LIST OF MAJOR PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
TABLE 4 OVERVIEW OF PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
5.13 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 OVERACTIVE BLADDER TREATMENT MARKET:
PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT FROM NEW ENTRANTS
5.13.2 THREAT FROM SUBSTITUTES
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 BARGAINING POWER OF SUPPLIERS
5.13.5 DEGREE OF COMPETITION
5.14 PRICING ANALYSIS
TABLE 6 COST OF DRUGS USED IN OVERACTIVE BLADDER TREATMENT
IN VARIOUS REGIONS (GENERICS)
TABLE 7 COST OF BOTOX AND NEUROMODULATION USED IN OVERACTIVE
BLADDER TREATMENT IN VARIOUS REGIONS
TABLE 8 COST OF BRANDED DRUGS USED IN OVERACTIVE BLADDER
TREATMENT IN VARIOUS REGIONS
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 22 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON THE BUYING PROCESS
FIGURE 23 KEY BUYING CRITERIA FOR OVERACTIVE BLADDER TREATMENT PRODUCTS AMONG END USERS
5.16 PIPELINE ANALYSIS
FIGURE 24 PIPELINE ANALYSIS: PHASES OF DRUGS IN CLINICAL TRIALS
6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 9 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 10 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2 MIRABEGRON
6.2.1 FEWER SIDE EFFECTS COMPARED WITH ANTICHOLINERGICS ARE LIKELY TO PROPEL THE GROWTH OF THIS MARKET SEGMENT
TABLE 11 OVERACTIVE BLADDER TREATMENT MARKET FOR MIRABEGRON, BY REGION, 2020–2027 (USD MILLION)
6.3 ANTICHOLINERGICS
TABLE 12 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
6.3.1 SOLIFENACIN
6.3.1.1 Solifenacin is more effective than other anticholinergics in reducing the frequency of incontinence—a key factor driving market growth
TABLE 14 OVERACTIVE BLADDER TREATMENT MARKET FOR SOLIFENACIN, BY REGION, 2020–2027 (USD MILLION)
6.3.2 OXYBUTYNIN
6.3.2.1 Oxybutynin is the most widely prescribed anticholinergic drug in the OAB market
TABLE 15 OVERACTIVE BLADDER TREATMENT MARKET FOR OXYBUTYNIN, BY REGION, 2020–2027 (USD MILLION)
6.3.3 FESOTERODINE
6.3.3.1 Fesoterodine exhibits antimuscarinic effects on the muscarinic acetylcholine receptors in the detrusor muscle, leading to a decrease in bladder contractions
TABLE 16 OVERACTIVE BLADDER TREATMENT MARKET FOR FESOTERODINE, BY REGION, 2020–2027 (USD MILLION)
6.3.4 DARIFENACIN
6.3.4.1 Cost of darifenacin is higher than other anticholinergics, which is likely to restrain market growth to a certain extent
TABLE 17 OVERACTIVE BLADDER TREATMENT MARKET FOR DARIFENACIN, BY REGION, 2020–2027 (USD MILLION)
6.3.5 TOLTERODINE
6.3.5.1 Tolterodine is the third-most-prescribed drug for OAB as it has fewer side effects and offers long-term clinical efficacy
TABLE 18 OVERACTIVE BLADDER TREATMENT MARKET FOR TOLTERODINE, BY REGION, 2020–2027 (USD MILLION)
6.3.6 TROSPIUM
6.3.6.1 Trospium is associated with a lower incidence of dry mouth, as a result of which its discontinuation rate is relatively low
TABLE 19 OVERACTIVE BLADDER TREATMENT MARKET FOR TROSPIUM, BY REGION, 2020–2027 (USD MILLION)
6.3.7 OTHER ANTICHOLINERGICS
TABLE 20 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER ANTICHOLINERGICS, BY REGION, 2020–2027 (USD MILLION)
6.4 BOTOX
6.4.1 HIGHER EFFICACY OF BOTOX THAN ANTICHOLINERGICS MAKES IT A POPULAR TREATMENT ALTERNATIVE
TABLE 21 OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION, 2020–2027 (USD MILLION)
6.5 NEUROMODULATION
6.5.1 INCREASING ADOPTION OF NEUROMODULATION FOR OVERACTIVE BLADDER TREATMENT TO DRIVE GROWTH IN THIS MARKET SEGMENT
TABLE 22 OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROMODULATION, BY REGION, 2020–2027 (USD MILLION)
6.6 OTHER TREATMENTS
TABLE 23 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER TREATMENTS, BY REGION, 2020–2027 (USD MILLION)
7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE
7.1 INTRODUCTION
TABLE 24 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
7.2 IDIOPATHIC OVERACTIVE BLADDER SYNDROME
7.2.1 AVAILABILITY OF REIMBURSEMENTS FOR DRUGS USED TO TREAT IDIOPATHIC OAB TO FUEL GROWTH IN THIS MARKET
TABLE 25 IDIOPATHIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3 NEUROGENIC OVERACTIVE BLADDER SYNDROME
TABLE 26 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 27 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
7.3.1 PARKINSON'S DISEASE
7.3.1.1 Increased use of anticholinergics and beta-adrenergic agonists for the treatment of Parkinson’s disease to drive market growth
TABLE 28 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR PARKINSON’S DISEASE, BY REGION, 2020–2027 (USD MILLION)
7.3.2 STROKES
7.3.2.1 Rising prevalence of strokes to increase the incidence of OAB and fuel the demand for OAB treatment
TABLE 29 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR STROKES, BY REGION, 2020–2027 (USD MILLION)
7.3.3 MULTIPLE SCLEROSIS
7.3.3.1 Favorable reimbursement policies to support the growth of the
OAB treatment market for MS
TABLE 30 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020–2027 (USD MILLION)
7.3.4 SPINAL CORD INJURIES
7.3.4.1 High prevalence of bladder overactivity in SCI contributes to the growth of the neurogenic bladder overactivity treatment market
TABLE 31 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR SPINAL CORD INJURIES, BY REGION, 2020–2027 (USD MILLION)
7.3.5 OTHER DISORDERS
TABLE 32 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER DISORDERS, BY REGION, 2020–2027 (USD MILLION)
8 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION
8.1 INTRODUCTION
TABLE 33 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
TABLE 34 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.2.1 US
8.2.1.1 Favorable reimbursement policies make the US the largest market for bladder overactivity treatment
TABLE 39 US: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 40 US: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 41 US: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 42 US: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Increased use of and demand for BOTOX to treat overactive bladder to drive market growth in Canada
TABLE 43 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 44 CANADA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 45 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 46 CANADA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3 EUROPE
TABLE 47 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 49 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 50 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 51 EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Aging population and a high prevalence of OAB, especially in women, are expected to increase target patient groups in Germany
TABLE 52 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 53 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 54 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 55 GERMANY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.2 UK
8.3.2.1 Initiatives and awareness campaigns in the UK to drive growth
in the OAB market
TABLE 56 ANNUAL COST OF OVERACTIVE BLADDER TREATMENT IN THE UK
TABLE 57 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 UK: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 59 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 60 UK: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Low reimbursement rate in France compared to other countries may limit market growth to a certain extent
TABLE 61 REIMBURSEMENT RATES FOR OVERACTIVE BLADDER TREATMENT IN FRANCE
TABLE 62 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 63 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 65 FRANCE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.4 ITALY
8.3.4.1 Italian pharmaceutical industry is expected to offer lucrative growth opportunities to OAB drug manufacturers
TABLE 66 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 ITALY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 68 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 69 ITALY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.5 SPAIN
8.3.5.1 Changing demographics and high OAB prevalence in Spain offer significant growth opportunities for the bladder overactivity treatment market
TABLE 70 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 71 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 73 SPAIN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.6 REST OF EUROPE
TABLE 74 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 77 REST OF EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
TABLE 78 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 80 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 81 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 82 ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Advancements in treatment options to fuel growth
in the market in Japan
TABLE 83 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 86 JAPAN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Growing adoption of BOTOX for OAB treatment makes China a lucrative market
TABLE 87 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 88 CHINA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 89 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 90 CHINA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.3 INDIA
8.4.3.1 India is the world’s largest producer of generic drugs— a key factor driving market growth
TABLE 91 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 92 INDIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 93 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 94 INDIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.4 AUSTRALIA
8.4.4.1 Growing aging population is likely to increase the number of patients suffering from OAB in Australia—a major factor supporting the growth of this market
TABLE 95 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 98 AUSTRALIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.5 REST OF ASIA PACIFIC
TABLE 99 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 100 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 101 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 102 REST OF ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5 LATIN AMERICA
TABLE 103 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 105 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 107 LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5.1 BRAZIL
8.5.1.1 Increased use of overactive bladder drugs in the country to
drive growth in the market
FIGURE 27 DISTRIBUTION OF POPULATION IN BRAZIL (ABOVE-60 AGE GROUP), 2004–2050
TABLE 108 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 110 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 111 BRAZIL: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5.2 MEXICO
8.5.2.1 Rising prevalence of OAB to drive growth in the market in Mexico
TABLE 112 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 113 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 114 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 115 MEXICO: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5.3 REST OF LATIN AMERICA
TABLE 116 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 118 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 119 REST OF LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.6 MIDDLE EAST & AFRICA
8.6.1 RISING AWARENESS OF OAB IS LIKELY TO DRIVE THE GROWTH OF THE MARKET IN THE MIDDLE EAST & AFRICA
TABLE 120 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 121 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 123 MIDDLE EAST & AFRICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 28 OVERACTIVE BLADDER TREATMENT MARKET: STRATEGIES ADOPTED
BY KEY PLAYERS
9.3 MARKET SHARE ANALYSIS
FIGURE 29 OVERACTIVE BLADDER TREATMENT MARKET: MARKET
SHARE ANALYSIS OF KEY PLAYERS (2021)
TABLE 124 OVERACTIVE BLADDER TREATMENT MARKET: DEGREE OF COMPETITION
9.4 REVENUE ANALYSIS
FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)
9.5 COMPANY EVALUATION QUADRANT
9.5.1 STARS
9.5.2 EMERGING LEADERS
9.5.3 PERVASIVE PLAYERS
9.5.4 PARTICIPANTS
FIGURE 31 OVERACTIVE BLADDER TREATMENT MARKET:
COMPANY EVALUATION MATRIX, 2021
9.6 COMPETITIVE BENCHMARKING OF TOP 20 PLAYERS
9.6.1 COMPANY FOOTPRINT (20 COMPANIES)
TABLE 125 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN
THE OVERACTIVE BLADDER TREATMENT MARKET
9.6.2 COMPANY PRODUCT FOOTPRINT (20 COMPANIES)
TABLE 126 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN
THE OVERACTIVE BLADDER TREATMENT MARKET
9.6.3 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
TABLE 127 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
IN THE OVERACTIVE BLADDER TREATMENT MARKET
9.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES
9.7.1 PROGRESSIVE COMPANIES
9.7.2 STARTING BLOCKS
9.7.3 RESPONSIVE COMPANIES
9.7.4 DYNAMIC COMPANIES
FIGURE 32 OVERACTIVE BLADDER TREATMENT MARKET:
COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
9.7.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
TABLE 128 OVERACTIVE BLADDER TREATMENT MARKET: DETAILED LIST OF
KEY START-UPS/SMES
TABLE 129 OVERACTIVE BLADDER TREATMENT MARKET:
COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
9.8 COMPETITIVE SCENARIO AND TRENDS
9.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 130 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MAY 2022
9.8.2 DEALS
TABLE 131 DEALS, JANUARY 2019–MAY 2022
10 COMPANY PROFILES
10.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 ASTELLAS PHARMA INC.
TABLE 132 ASTELLAS PHARMA INC.: BUSINESS OVERVIEW
FIGURE 33 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2021)
10.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE 133 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
10.1.3 PFIZER INC.
TABLE 134 PFIZER INC.: BUSINESS OVERVIEW
FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2021)
10.1.4 ABBVIE INC.
TABLE 135 ABBVIE INC.: BUSINESS OVERVIEW
FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2021)
10.1.5 VIATRIS INC.
TABLE 136 VIATRIS INC.: BUSINESS OVERVIEW
FIGURE 37 VIATRIS INC.: COMPANY SNAPSHOT (2021)
10.1.6 HISAMITSU PHARMACEUTICAL CO., INC.
TABLE 137 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW
FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2020)
10.1.7 JOHNSON & JOHNSON SERVICES, INC.
TABLE 138 JOHNSON & JOHNSON SERVICES, INC.: BUSINESS OVERVIEW
FIGURE 39 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2021)
10.1.8 ENDO PHARMACEUTICALS INC.
TABLE 139 ENDO PHARMACEUTICALS INC.: BUSINESS OVERVIEW
FIGURE 40 ENDO PHARMACEUTICALS INC.: COMPANY SNAPSHOT
10.1.9 LUPIN
TABLE 140 LUPIN: BUSINESS OVERVIEW
FIGURE 41 LUPIN: COMPANY SNAPSHOT (2021)
10.1.10 AMNEAL PHARMACEUTICALS LLC
TABLE 141 AMNEAL PHARMACEUTICALS LLC: BUSINESS OVERVIEW
FIGURE 42 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2021)
10.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 142 SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 43 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
10.1.12 GLENMARK
TABLE 143 GLENMARK: BUSINESS OVERVIEW
FIGURE 44 GLENMARK: COMPANY SNAPSHOT (2021)
10.1.13 MACLEODS PHARMACEUTICALS LTD.
TABLE 144 MACLEODS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
FIGURE 45 MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)
10.1.14 MEDTRONIC
TABLE 145 MEDTRONIC: BUSINESS OVERVIEW
FIGURE 46 MEDTRONIC: COMPANY SNAPSHOT (2021)
10.1.15 AJANTA PHARMA
TABLE 146 AJANTA PHARMA: BUSINESS OVERVIEW
FIGURE 47 AJANTA PHARMA: COMPANY SNAPSHOT (2021)
10.1.16 GRANULES INDIA LIMITED
TABLE 147 GRANULES INDIA LIMITED: BUSINESS OVERVIEW
FIGURE 48 GRANULES INDIA LIMITED: COMPANY SNAPSHOT (2021)
10.2 OTHER PLAYERS
10.2.1 UROVANT SCIENCES
TABLE 148 UROVANT SCIENCES: BUSINESS OVERVIEW
10.2.2 APOTEX INC.
TABLE 149 APOTEX INC.: BUSINESS OVERVIEW
10.2.3 LABORIE
TABLE 150 LABORIE: BUSINESS OVERVIEW
10.2.4 INTAS PHARMACEUTICALS LTD.
TABLE 151 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
10.2.5 BAYER AG
TABLE 152 BAYER AG: BUSINESS OVERVIEW
10.2.6 MEDYTOX
TABLE 153 MEDYTOX: BUSINESS OVERVIEW
10.2.7 ALTHERX PHARMACEUTICALS
TABLE 154 ALTHERX PHARMACEUTICALS: BUSINESS OVERVIEW
10.2.8 TAIHO PHARMACEUTICAL CO., LTD.
TABLE 155 TAIHO PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW
10.2.9 HUGEL, INC.
TABLE 156 HUGEL, INC.: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 AVAILABLE CUSTOMIZATIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.1.1 PRIMARY RESEARCH
FIGURE 2 OVERACTIVE BLADDER TREATMENT MARKET: PRIMARY RESPONDENTS
2.1.2 TOP-DOWN AND BOTTOM-UP APPROACHES
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION
2.2 DATA TRIANGULATION APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.2.1 SECONDARY RESEARCH
2.2.2 COVID-19-SPECIFIC ASSUMPTIONS
2.3 RESEARCH LIMITATIONS
2.4 RISK ASSESSMENT
2.5 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
2.5.1 SUPPLY SIDE
2.5.2 DEMAND SIDE
2.5.2.1 Insights from primary experts
3 EXECUTIVE SUMMARY
FIGURE 6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE
2022 VS. 2027 (USD MILLION)
FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE OVERACTIVE
BLADDER TREATMENT MARKET
4 PREMIUM INSIGHTS
4.1 OVERACTIVE BLADDER TREATMENT MARKET OVERVIEW
FIGURE 9 RISING PREVALENCE OF OVERACTIVE BLADDER SYNDROME AND FAVORABLE REIMBURSEMENT POLICIES ARE KEY FACTORS DRIVING MARKET GROWTH
4.2 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY TYPE AND COUNTRY (2021)
FIGURE 10 MIRABEGRON ACCOUNTED FOR THE LARGEST SHARE OF
THE ASIA PACIFIC MARKET IN 2021
4.3 OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY DISEASE TYPE, 2022 VS. 2027
FIGURE 11 IDIOPATHIC OVERACTIVE BLADDER SYNDROME SEGMENT WILL
CONTINUE TO DOMINATE THE MARKET IN 2027
4.4 OVERACTIVE BLADDER TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 12 US TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 13 OVERACTIVE BLADDER TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 OVERACTIVE BLADDER TREATMENT MARKET: IMPACT ANALYSIS
5.2.1 MARKET DRIVERS
5.2.1.1 Rising prevalence of overactive bladder syndrome
5.2.1.2 Rapidly aging population and subsequent rise in incidence of diseases characterized by OAB
FIGURE 14 PROJECTED GROWTH IN THE ELDERLY POPULATION ABOVE 60, 2015 VS. 2030 VS. 2050
5.2.1.3 Development and use of innovative intravesical therapies
5.2.1.4 Growing R&D investments and the launch of novel therapies
in the coming years
5.2.2 MARKET RESTRAINTS
5.2.2.1 Frequent product recalls
5.2.2.2 Increased side effects of anticholinergic drugs
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Novel treatments, robust pipelines, and patent cliff of certain drugs
5.2.4 MARKET CHALLENGES
5.2.4.1 Social stigma and lack of awareness about OAB
5.3 IMPACT OF UNCERTAINTIES ON THE OVERACTIVE BLADDER TREATMENT MARKET
FIGURE 15 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE OVERACTIVE BLADDER TREATMENT MARKET
5.4 IMPACT OF COVID-19 ON THE OVERACTIVE BLADDER TREATMENT MARKET
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 16 REVENUE SHIFT AND NEW POCKETS FOR THE OVERACTIVE BLADDER TREATMENT MARKET
5.6 VALUE CHAIN ANALYSIS
FIGURE 17 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 18 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF
PROMINENT COMPANIES
5.8 ECOSYSTEM ANALYSIS
FIGURE 19 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY
FIGURE 20 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES INDUSTRY
5.9 REGULATORY SCENARIO
5.9.1 PHARMACEUTICAL INDUSTRY
5.9.1.1 Regulatory requirements
5.9.1.1.1 EU regulations
5.9.1.1.2 US regulations
5.9.2 MEDICAL DEVICE INDUSTRY
5.9.2.1 Regulatory requirements
5.9.2.1.1 EU regulations
5.9.2.1.2 US regulations
TABLE 2 LIST OF REGULATORY AUTHORITIES
5.10 TECHNOLOGY ANALYSIS
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 3 OVERACTIVE BLADDER TREATMENT MARKET: LIST OF
CONFERENCES AND EVENTS
5.12 PATENT ANALYSIS
FIGURE 21 LIST OF MAJOR PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
TABLE 4 OVERVIEW OF PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
5.13 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 OVERACTIVE BLADDER TREATMENT MARKET:
PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT FROM NEW ENTRANTS
5.13.2 THREAT FROM SUBSTITUTES
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 BARGAINING POWER OF SUPPLIERS
5.13.5 DEGREE OF COMPETITION
5.14 PRICING ANALYSIS
TABLE 6 COST OF DRUGS USED IN OVERACTIVE BLADDER TREATMENT
IN VARIOUS REGIONS (GENERICS)
TABLE 7 COST OF BOTOX AND NEUROMODULATION USED IN OVERACTIVE
BLADDER TREATMENT IN VARIOUS REGIONS
TABLE 8 COST OF BRANDED DRUGS USED IN OVERACTIVE BLADDER
TREATMENT IN VARIOUS REGIONS
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 22 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON THE BUYING PROCESS
FIGURE 23 KEY BUYING CRITERIA FOR OVERACTIVE BLADDER TREATMENT PRODUCTS AMONG END USERS
5.16 PIPELINE ANALYSIS
FIGURE 24 PIPELINE ANALYSIS: PHASES OF DRUGS IN CLINICAL TRIALS
6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 9 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 10 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2 MIRABEGRON
6.2.1 FEWER SIDE EFFECTS COMPARED WITH ANTICHOLINERGICS ARE LIKELY TO PROPEL THE GROWTH OF THIS MARKET SEGMENT
TABLE 11 OVERACTIVE BLADDER TREATMENT MARKET FOR MIRABEGRON, BY REGION, 2020–2027 (USD MILLION)
6.3 ANTICHOLINERGICS
TABLE 12 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
6.3.1 SOLIFENACIN
6.3.1.1 Solifenacin is more effective than other anticholinergics in reducing the frequency of incontinence—a key factor driving market growth
TABLE 14 OVERACTIVE BLADDER TREATMENT MARKET FOR SOLIFENACIN, BY REGION, 2020–2027 (USD MILLION)
6.3.2 OXYBUTYNIN
6.3.2.1 Oxybutynin is the most widely prescribed anticholinergic drug in the OAB market
TABLE 15 OVERACTIVE BLADDER TREATMENT MARKET FOR OXYBUTYNIN, BY REGION, 2020–2027 (USD MILLION)
6.3.3 FESOTERODINE
6.3.3.1 Fesoterodine exhibits antimuscarinic effects on the muscarinic acetylcholine receptors in the detrusor muscle, leading to a decrease in bladder contractions
TABLE 16 OVERACTIVE BLADDER TREATMENT MARKET FOR FESOTERODINE, BY REGION, 2020–2027 (USD MILLION)
6.3.4 DARIFENACIN
6.3.4.1 Cost of darifenacin is higher than other anticholinergics, which is likely to restrain market growth to a certain extent
TABLE 17 OVERACTIVE BLADDER TREATMENT MARKET FOR DARIFENACIN, BY REGION, 2020–2027 (USD MILLION)
6.3.5 TOLTERODINE
6.3.5.1 Tolterodine is the third-most-prescribed drug for OAB as it has fewer side effects and offers long-term clinical efficacy
TABLE 18 OVERACTIVE BLADDER TREATMENT MARKET FOR TOLTERODINE, BY REGION, 2020–2027 (USD MILLION)
6.3.6 TROSPIUM
6.3.6.1 Trospium is associated with a lower incidence of dry mouth, as a result of which its discontinuation rate is relatively low
TABLE 19 OVERACTIVE BLADDER TREATMENT MARKET FOR TROSPIUM, BY REGION, 2020–2027 (USD MILLION)
6.3.7 OTHER ANTICHOLINERGICS
TABLE 20 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER ANTICHOLINERGICS, BY REGION, 2020–2027 (USD MILLION)
6.4 BOTOX
6.4.1 HIGHER EFFICACY OF BOTOX THAN ANTICHOLINERGICS MAKES IT A POPULAR TREATMENT ALTERNATIVE
TABLE 21 OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION, 2020–2027 (USD MILLION)
6.5 NEUROMODULATION
6.5.1 INCREASING ADOPTION OF NEUROMODULATION FOR OVERACTIVE BLADDER TREATMENT TO DRIVE GROWTH IN THIS MARKET SEGMENT
TABLE 22 OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROMODULATION, BY REGION, 2020–2027 (USD MILLION)
6.6 OTHER TREATMENTS
TABLE 23 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER TREATMENTS, BY REGION, 2020–2027 (USD MILLION)
7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE
7.1 INTRODUCTION
TABLE 24 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
7.2 IDIOPATHIC OVERACTIVE BLADDER SYNDROME
7.2.1 AVAILABILITY OF REIMBURSEMENTS FOR DRUGS USED TO TREAT IDIOPATHIC OAB TO FUEL GROWTH IN THIS MARKET
TABLE 25 IDIOPATHIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3 NEUROGENIC OVERACTIVE BLADDER SYNDROME
TABLE 26 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 27 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
7.3.1 PARKINSON'S DISEASE
7.3.1.1 Increased use of anticholinergics and beta-adrenergic agonists for the treatment of Parkinson’s disease to drive market growth
TABLE 28 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR PARKINSON’S DISEASE, BY REGION, 2020–2027 (USD MILLION)
7.3.2 STROKES
7.3.2.1 Rising prevalence of strokes to increase the incidence of OAB and fuel the demand for OAB treatment
TABLE 29 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR STROKES, BY REGION, 2020–2027 (USD MILLION)
7.3.3 MULTIPLE SCLEROSIS
7.3.3.1 Favorable reimbursement policies to support the growth of the
OAB treatment market for MS
TABLE 30 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020–2027 (USD MILLION)
7.3.4 SPINAL CORD INJURIES
7.3.4.1 High prevalence of bladder overactivity in SCI contributes to the growth of the neurogenic bladder overactivity treatment market
TABLE 31 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR SPINAL CORD INJURIES, BY REGION, 2020–2027 (USD MILLION)
7.3.5 OTHER DISORDERS
TABLE 32 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER DISORDERS, BY REGION, 2020–2027 (USD MILLION)
8 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION
8.1 INTRODUCTION
TABLE 33 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
TABLE 34 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.2.1 US
8.2.1.1 Favorable reimbursement policies make the US the largest market for bladder overactivity treatment
TABLE 39 US: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 40 US: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 41 US: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 42 US: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Increased use of and demand for BOTOX to treat overactive bladder to drive market growth in Canada
TABLE 43 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 44 CANADA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 45 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 46 CANADA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3 EUROPE
TABLE 47 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 49 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 50 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 51 EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Aging population and a high prevalence of OAB, especially in women, are expected to increase target patient groups in Germany
TABLE 52 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 53 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 54 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 55 GERMANY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.2 UK
8.3.2.1 Initiatives and awareness campaigns in the UK to drive growth
in the OAB market
TABLE 56 ANNUAL COST OF OVERACTIVE BLADDER TREATMENT IN THE UK
TABLE 57 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 UK: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 59 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 60 UK: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Low reimbursement rate in France compared to other countries may limit market growth to a certain extent
TABLE 61 REIMBURSEMENT RATES FOR OVERACTIVE BLADDER TREATMENT IN FRANCE
TABLE 62 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 63 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 65 FRANCE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.4 ITALY
8.3.4.1 Italian pharmaceutical industry is expected to offer lucrative growth opportunities to OAB drug manufacturers
TABLE 66 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 ITALY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 68 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 69 ITALY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.5 SPAIN
8.3.5.1 Changing demographics and high OAB prevalence in Spain offer significant growth opportunities for the bladder overactivity treatment market
TABLE 70 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 71 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 73 SPAIN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.6 REST OF EUROPE
TABLE 74 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 77 REST OF EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
TABLE 78 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 80 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 81 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 82 ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Advancements in treatment options to fuel growth
in the market in Japan
TABLE 83 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 86 JAPAN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Growing adoption of BOTOX for OAB treatment makes China a lucrative market
TABLE 87 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 88 CHINA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 89 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 90 CHINA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.3 INDIA
8.4.3.1 India is the world’s largest producer of generic drugs— a key factor driving market growth
TABLE 91 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 92 INDIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 93 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 94 INDIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.4 AUSTRALIA
8.4.4.1 Growing aging population is likely to increase the number of patients suffering from OAB in Australia—a major factor supporting the growth of this market
TABLE 95 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 98 AUSTRALIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.5 REST OF ASIA PACIFIC
TABLE 99 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 100 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 101 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 102 REST OF ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5 LATIN AMERICA
TABLE 103 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 105 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 107 LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5.1 BRAZIL
8.5.1.1 Increased use of overactive bladder drugs in the country to
drive growth in the market
FIGURE 27 DISTRIBUTION OF POPULATION IN BRAZIL (ABOVE-60 AGE GROUP), 2004–2050
TABLE 108 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 110 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 111 BRAZIL: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5.2 MEXICO
8.5.2.1 Rising prevalence of OAB to drive growth in the market in Mexico
TABLE 112 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 113 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 114 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 115 MEXICO: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5.3 REST OF LATIN AMERICA
TABLE 116 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 118 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 119 REST OF LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.6 MIDDLE EAST & AFRICA
8.6.1 RISING AWARENESS OF OAB IS LIKELY TO DRIVE THE GROWTH OF THE MARKET IN THE MIDDLE EAST & AFRICA
TABLE 120 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 121 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 123 MIDDLE EAST & AFRICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 28 OVERACTIVE BLADDER TREATMENT MARKET: STRATEGIES ADOPTED
BY KEY PLAYERS
9.3 MARKET SHARE ANALYSIS
FIGURE 29 OVERACTIVE BLADDER TREATMENT MARKET: MARKET
SHARE ANALYSIS OF KEY PLAYERS (2021)
TABLE 124 OVERACTIVE BLADDER TREATMENT MARKET: DEGREE OF COMPETITION
9.4 REVENUE ANALYSIS
FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)
9.5 COMPANY EVALUATION QUADRANT
9.5.1 STARS
9.5.2 EMERGING LEADERS
9.5.3 PERVASIVE PLAYERS
9.5.4 PARTICIPANTS
FIGURE 31 OVERACTIVE BLADDER TREATMENT MARKET:
COMPANY EVALUATION MATRIX, 2021
9.6 COMPETITIVE BENCHMARKING OF TOP 20 PLAYERS
9.6.1 COMPANY FOOTPRINT (20 COMPANIES)
TABLE 125 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN
THE OVERACTIVE BLADDER TREATMENT MARKET
9.6.2 COMPANY PRODUCT FOOTPRINT (20 COMPANIES)
TABLE 126 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN
THE OVERACTIVE BLADDER TREATMENT MARKET
9.6.3 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
TABLE 127 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
IN THE OVERACTIVE BLADDER TREATMENT MARKET
9.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES
9.7.1 PROGRESSIVE COMPANIES
9.7.2 STARTING BLOCKS
9.7.3 RESPONSIVE COMPANIES
9.7.4 DYNAMIC COMPANIES
FIGURE 32 OVERACTIVE BLADDER TREATMENT MARKET:
COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
9.7.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
TABLE 128 OVERACTIVE BLADDER TREATMENT MARKET: DETAILED LIST OF
KEY START-UPS/SMES
TABLE 129 OVERACTIVE BLADDER TREATMENT MARKET:
COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
9.8 COMPETITIVE SCENARIO AND TRENDS
9.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 130 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MAY 2022
9.8.2 DEALS
TABLE 131 DEALS, JANUARY 2019–MAY 2022
10 COMPANY PROFILES
10.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 ASTELLAS PHARMA INC.
TABLE 132 ASTELLAS PHARMA INC.: BUSINESS OVERVIEW
FIGURE 33 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2021)
10.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE 133 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
10.1.3 PFIZER INC.
TABLE 134 PFIZER INC.: BUSINESS OVERVIEW
FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2021)
10.1.4 ABBVIE INC.
TABLE 135 ABBVIE INC.: BUSINESS OVERVIEW
FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2021)
10.1.5 VIATRIS INC.
TABLE 136 VIATRIS INC.: BUSINESS OVERVIEW
FIGURE 37 VIATRIS INC.: COMPANY SNAPSHOT (2021)
10.1.6 HISAMITSU PHARMACEUTICAL CO., INC.
TABLE 137 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW
FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2020)
10.1.7 JOHNSON & JOHNSON SERVICES, INC.
TABLE 138 JOHNSON & JOHNSON SERVICES, INC.: BUSINESS OVERVIEW
FIGURE 39 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2021)
10.1.8 ENDO PHARMACEUTICALS INC.
TABLE 139 ENDO PHARMACEUTICALS INC.: BUSINESS OVERVIEW
FIGURE 40 ENDO PHARMACEUTICALS INC.: COMPANY SNAPSHOT
10.1.9 LUPIN
TABLE 140 LUPIN: BUSINESS OVERVIEW
FIGURE 41 LUPIN: COMPANY SNAPSHOT (2021)
10.1.10 AMNEAL PHARMACEUTICALS LLC
TABLE 141 AMNEAL PHARMACEUTICALS LLC: BUSINESS OVERVIEW
FIGURE 42 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2021)
10.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 142 SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 43 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
10.1.12 GLENMARK
TABLE 143 GLENMARK: BUSINESS OVERVIEW
FIGURE 44 GLENMARK: COMPANY SNAPSHOT (2021)
10.1.13 MACLEODS PHARMACEUTICALS LTD.
TABLE 144 MACLEODS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
FIGURE 45 MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)
10.1.14 MEDTRONIC
TABLE 145 MEDTRONIC: BUSINESS OVERVIEW
FIGURE 46 MEDTRONIC: COMPANY SNAPSHOT (2021)
10.1.15 AJANTA PHARMA
TABLE 146 AJANTA PHARMA: BUSINESS OVERVIEW
FIGURE 47 AJANTA PHARMA: COMPANY SNAPSHOT (2021)
10.1.16 GRANULES INDIA LIMITED
TABLE 147 GRANULES INDIA LIMITED: BUSINESS OVERVIEW
FIGURE 48 GRANULES INDIA LIMITED: COMPANY SNAPSHOT (2021)
10.2 OTHER PLAYERS
10.2.1 UROVANT SCIENCES
TABLE 148 UROVANT SCIENCES: BUSINESS OVERVIEW
10.2.2 APOTEX INC.
TABLE 149 APOTEX INC.: BUSINESS OVERVIEW
10.2.3 LABORIE
TABLE 150 LABORIE: BUSINESS OVERVIEW
10.2.4 INTAS PHARMACEUTICALS LTD.
TABLE 151 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
10.2.5 BAYER AG
TABLE 152 BAYER AG: BUSINESS OVERVIEW
10.2.6 MEDYTOX
TABLE 153 MEDYTOX: BUSINESS OVERVIEW
10.2.7 ALTHERX PHARMACEUTICALS
TABLE 154 ALTHERX PHARMACEUTICALS: BUSINESS OVERVIEW
10.2.8 TAIHO PHARMACEUTICAL CO., LTD.
TABLE 155 TAIHO PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW
10.2.9 HUGEL, INC.
TABLE 156 HUGEL, INC.: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 AVAILABLE CUSTOMIZATIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
